Brand new #MOA in #Rx of #skin #lupus! #Litifilimab - acts on #dendritic cells ⬇️decreases #chemokines & #cytokines +RCT in #cutaneous features of lupus N=93 2:1 randomized #liti v #pbo Rapid onset <4wks HIgh #CLASI response #EULARbest #EULAR226 @RheumNow @eular_org POS438 https://t.co/TXqggO1jCU

• https://x.com/Janetbirdope/status/2062459007638389179/photo/1
• https://x.com/Janetbirdope/status/2062459007638389179/photo/1

#EULAR2026 OP Are we closer to controlled trials of CAR-T? Miv-cel KYV-101 autologous CD19 CAR-T reported efficacy and safety profile in 6 patients with severe refractory #RA (median prior bDMARDs: 6) in Phase I COMPARE. Will proceed to Phase II with RTX as a comparator @RheumNow https://t.co/Rb4BFgBDZE

• https://x.com/Yuz6Yusof/status/2062458622936760812/photo/1

FASTLANE study Ph4 RCT on TOFA+NPX vs. PBO+NPX for early active axSpA TOFA arm significantly achieved inactive dse vs. PBO (p=0.006) at wk 16. Similar results seen in secondary efficacy endpts. Interesting results supporting TOFA use AbsOP0241 @RheumNow #EULAR2026 #EULARBest https://t.co/PQYzE1zm0h

• https://x.com/RHEUMarampa/status/2062458264655134775/photo/1

A new MoA that does not meet it's primary endpoint in RA SPECIFI-RA Ph2b oral TNFR1 signal inhibitor balinatunfib ACR20 wk12 NOT significantly diff vs PBO ~48.5–61.8% across doses vs 52.3% PBO Secondary BALI 200 mg QD: ACR50: 36.9% vs 18.5% (nominal p=0.0179) Mechanistic https://t.co/hmZ93JisiO

• https://x.com/AurelieRheumo/status/2062454356176171351/photo/1
• https://x.com/AurelieRheumo/status/2062454356176171351/photo/1
• https://x.com/AurelieRheumo/status/2062454356176171351/photo/1

#EULAR2026 OP0166 In a phase III RCT in dermatomyositis, brepocitinib, first in class selective SyK-i and JAK1-i showed rapid meaningful improvement in cutaneous DM as early as Week 4 vs PBO. Exciting option and is under FDA Priority Review for approval @RheumNow #EULARBest https://t.co/9b0WurgBkN

• https://x.com/Yuz6Yusof/status/2062469410732790078/photo/1

Mean disease duration in the tofacitinib arm was just 0.57 years since diagnosis. This is genuinely early #axSpA and JAK1 inhibition achieves near-remission rates above placebo. An oral option for early axSpA Abstr#0241 @RheumNow #EUlAR2026

#OP0219 at #EULAR2026: Real-world ASTER data suggest DORIS remission & LLDAS are achievable with anifrolumab in routine practice, assoc w ⬇️risk of organ damage accrual. Over 12m, 43% attained DORIS remission & 74% LLDAS. Low serious adverse event rates reported. @RheumNow

#EULAR2026 OP0216 With the advances in biologics/cell-based therapies in #SLE, we need to define “severe refractory.” Data-driven analysis from 13 nations suggested: SLEDAI≥6 + PGA>1 + mild-moderate or severe flare (MMSf) + GC≥10 +IS. Need validation study before use @RheumNow https://t.co/K2dMSQUIgB

• https://x.com/Yuz6Yusof/status/2062436505902096486/photo/1

💉 Is Izokibep (Novel IL-17i) durable in PsA at 1yr? Phase2b/3 RCT: ~50% ACR50 at week in 343pts OP073 #EULAR2026 @RheumNow https://t.co/M3nrKFTA7c

• https://x.com/Nellziade/status/2062265661829611550/photo/1

#Rosnilimab works!! #PD1 agonist In #moderate to severe #RA showed fast deep responses in Ph2 #PBO CONTROLLED #rheumatoid #athritis Seemed NOT to have sig side effects compared to some PD1 drugs that ceased development in RA #EULAR2026 @RheumNow #OP0202 #EULARbest https://t.co/Jz92npXdgd

• https://x.com/Janetbirdope/status/2062440115578777860/photo/1
• https://x.com/Janetbirdope/status/2062440115578777860/photo/1

SUNSTAR head-to-head after failure of 1 (80+%)–2 prior b/tsDMARDs in RA TCZ vs. ABA Confirms what we already knew: -Primary endpoint CDAI change wk26 not different -Composite response (persistence + low disease activity + low steroid use) 51% vs 35% p=0.034 -Better response in https://t.co/002n3sWtKs

• https://x.com/AurelieRheumo/status/2062447221258232281/photo/1
• https://x.com/AurelieRheumo/status/2062447221258232281/photo/1
• https://x.com/AurelieRheumo/status/2062447221258232281/photo/1
• https://x.com/AurelieRheumo/status/2062447221258232281/photo/1

Tofacitinib achieved ASDAS inactive disease in 26.4% of patients with early #axSpA (back pain ≤2 years) vs 7.4% placebo at 16 weeks (p=0.006). First RCT of advanced therapy in very early axSpA Abstr#0241 @RheumNow #EULAR2026

What if we let RA patients choose ttmt? BACH RCT choice between Filgo / scTNFi vs. standard randomisation 55% JAKi vs 45% TNFi Higher ttmt satisfaction 46 vs 33 p=0.012 Less ttmt switches 6 vs 15 p=0.026 Less AE reported Better drug survival Shared decision making is key! https://t.co/1YS0y6YUEH

• https://x.com/AurelieRheumo/status/2062443937332154751/photo/1
• https://x.com/AurelieRheumo/status/2062443937332154751/photo/1
• https://x.com/AurelieRheumo/status/2062443937332154751/photo/1

#EULAR2026 OP002 More encouraging news in #Sjogren. A Phase II RCT in N=30 patients with ESSDAI=>5 and/or ESSPRI=>5: Anifrolumab (IFN-IR mAb) improved CRESS response vs PBO (80% vs 30%). Impressive effect size for other endpoints too. Need definitive Phase III RCT @RheumNow https://t.co/W3GbA3gKIs

• https://x.com/Yuz6Yusof/status/2062410158299332863/photo/1